Mats Hansen
Spago takes Tumorad-01 study to the next level
Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...
Spago’s CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago...
Tumorad clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical publicerar positiva prekliniska data
Prekliniska data med Spago Nanomedicals radionuklidkoncept Tumorad har...
Spago Nanomedical startar fas IIa-studie i endometrios
Lundabaserade Spago Nanomedical meddelade nyligen att bolaget fått...
Spago Nanomedical om höstens nyhetsflöde
Under andra kvartalet genomförde Lundabolaget Spago Nanomedical en...
Spago Nanomedical går mot klinik med Tumorad
Strax innan halvårsskiftet meddelade Lundabaserade Spago Nanomedical att...
Spago Nanomedical tar kliv med kapitalinjektion
Lundabolaget Spago Nanomedical tar in kapital via en...
Spago Nanomedical mot klinik med tydlig plan
First North-listade Spago Nanomedicals vd Mats Hansen berättade...
Spago Nanomedical om potentialen i projekten
Lundabaserade Spago Nanomedical publicerade nyligen årets första delårsrapport...
Spago Nanomedical blickar framåt
First North-listade Spago Nanomedical har inlett året med...
Spago Nanomedical om framstegen med Tumorad
Lundabaserade Spago Nanomedical presenterade under veckan positiva prekliniska...
